European Network of Individualized Treatment in Endometrial Cancer Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2016
NCT02725268
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

European Network of Individualized Treatment in Endometrial Cancer - ENITEC

Active Ingredients

Drugs in Phase 2 Trials (3)

paclitaxel (taxol) (1 trial)

sapanisertib (1 trial)

tak-117 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Endometrial Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3